Disuprazole
Disuprazole (U-69167) is an orally active benzimidazole proton pump inhibitor that inhibits gastric H+/K+-ATPase with an IC50 of 2 × 10-5 M. Disuprazole reduces gastric acid secretion by inhibiting gastric proton pump activity. Disuprazole can be used in research related to gastric acid secretion and peptic ulcer.
For research use only. We do not sell to patients.
- CAS No.: 99499-40-8
- Formula: C16H17N3OS2
- Molecular Weight:331.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
Hog gastric H+/K+-ATPase 20 μM (IC50) |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Disuprazole (s.c. or oral administration; single dose) inhibits gastric acid secretion in Carbachol (HY-B1208)-stimulated pylorus-ligated Shay rats, with ED50 values of < 1.0 mg/kg and 2.0-5.0 mg/kg, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 99499-40-8
-
Molecular Weight 331.46
-
Formula C16H17N3OS2
-
SMILES
O=S(CC1=NC=CC(SCC)=C1C)C2=NC3=C(N2)C=CC=C3
-
Synonyms
U-69167
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Disuprazole
- 99499-40-8
- U-69167
- U69167
- U 69167
- Proton Pump
- hydrophobic interactions
- Shay rat model
- CYP2C9 ligand
- rabbit gastric glands
- rat gastric (H+-K+)-ATPase
- extended conformation
- hydrophobic pocket of CYP2C9
- hog gastric (H+/K+)-ATPase
- water-mediated hydrogen-bonding networks
- heme
- gastric (H+/K+)-ATPase inhibitor
- Inhibitor
- inhibitor
- inhibit